cd4+ t cells
The T helper cells (Th cells), also known as CD4+ cells or CD4-positive cells, are a type of T cell that play an important role in the adaptive immune system. They aid the activity of other immune cells by releasing cytokines. They are considered essential in B cell antibody class switching, breaking cross-tolerance in dendritic cells, in the activation and growth of cytotoxic T cells, and in maximizing bactericidal activity of phagocytes such as macrophages and neutrophils. CD4+ cells are mature Th cells that express the surface protein CD4. Genetic variation in regulatory elements expressed by CD4+ cells determines susceptibility to a broad class of autoimmune diseases. — Wikipedia
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2016 (NCT02210104)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaT helper cell ↗
Also known as
- cd4+ t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02210104 | Phase 1 | Dec 1, 2016 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Texas at Houston |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2016 |